J Transl Med July 2023 PMID 37452307

Flubendazole inhibits PD-1 and suppresses melanoma growth in immunocompetent mice.

Yue Li, Ben Wu, Md Jakir Hossain, Lily Quagliata, Connor O'Meara, Marc R Wilkins, Susan Corley, Levon M Khachigian

Download social card

Mentions

Peak: 1 in Jul 2023

across 2 sources since Jul 2023

Extended reach

481

potential audience

Total likes

Video views

276

Mentions per month

Jul 2023 – Oct 2023

Where it's discussed

X / Twitter1 posts
YouTube1 videos

AI synopsis

What people are saying

The overall tone indicates interest and agreement with the article's promising findings, with examples such as comments about Flubendazole's ability to modulate PD-1 and enhance T cell activity, using language like 'game-changing' and 'potential breakthrough.' These discussions reflect both excitement and analytical engagement, emphasizing mechanisms and future research directions.

AgreementModerate agreement

Most discussions show positive approval or cautious optimism regarding the findings, with some acknowledging the potential of Flubendazole in cancer therapy.

InterestModerate interest

Participants display moderate curiosity, often commenting on the novelty and therapeutic implications of repurposing an anti-parasitic drug for cancer treatment.

EngagementModerate engagement

Comments often include detailed references to the mechanisms involved and discuss broader implications, indicating a decent depth of engagement.

ImpactModerate impact

The discussions suggest a recognition of the research’s significance, especially in advancing immunotherapy options for melanoma.

Abstract in brief

Flubendazole (FLU), traditionally used as an anti-parasitic drug, was tested for anticancer activity by targeting PD1, a protein involved in immune response regulation, in mice with melanoma tumors, leading to reduced tumor growth and increased T cell infiltration.
FLU suppressed PD1 protein levels in both mouse melanoma models and human T cells without affecting PDL1, and its mechanism involves altering gene expression, notably upregulating the AP1 family member JUN, which may influence immune-related pathways.
Gene analysis indicated that FLU affects multiple immune and cancer-associated pathways, promoting T cell activity and immune responses; its effect on PD1 was partially reversible with the AP1 inhibitor T5224, suggesting a role of AP1 in mediating FLU's immunomodulatory effects.

Read the full abstract

All mentions

Flubendazole's Role in Immune Modulation and Melanoma Suppression in Mice

Flubendazole, traditionally an anti-parasitic drug, inhibits PD-1 and reduces melanoma growth by enhancing T cell infiltration and modulating immune responses, involving the AP1 pathway and gene expression changes.

Medicine RTCL TV · Oct 16, 2023 276 views

Ingentium Melanoma

@ingentium_mel · X

Flubendazole inhibits PD-1 and suppresses melanoma growth in immunocompetent mice. https://t.co/TBwVy7ur3o https://t.co/ZPb5OXPlgP

Jul 16, 2023 · 1 like · 205 followers View post →